Search 

TransThera Biosciences is a Nanjing based biotech, founded in 2016, focusing on research and development of small molecules in oncology, inflammation, and cardiovascular diseases. Four assets have entered into global clinical development in past 4 years.

New.Fa.Dem. searches the new partners worldwide for the distribution of its own products.
New.Fa.Dem, a manufacturing company based in Italy and is authorized by Italian Agency of Drugs.
Conducts activities like R&D, Manufacturing, Distribution of ethical drugs, medical devices and cosmetics with own brand or private labeling.
Manufacturing of Creams, Gels, liquid, powder and suppositories.
Three important certifications:
• ISO 9001: 2015 for compliance with international quality management standards;
• ISO 13485: 2016 for congruence with the legislation relating to the quality of medical devices;
• GMP COMPLIANCE for the possession of authorizations and licenses for the production of pharmaceutical products.
Possibility of manufacturing medical devices and cosmetics of the same form in the facility in the near future.
Successfully present in Europe, Middle East and North Africa.
ISO Certifications for compliance of international standards of Quality Management and rules on the quality of Medical Devices.

Protheragen’s business is growing rapidly after founded in Ronkonkoma, New York in 2009. More offices have been established at different locations across China and the US ever since. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

To continue our development, part of our strategies requires us to constantly seeking high-quality novel drug research and development programs that are open to collaboration opportunities. Relying on strong industry resources and connections built up throughout the years, we welcome partnerships in the following structures: equity investment, intermediary service and project incubation.

Reistone BioPharma is a clinical-stage biotech company focused on developing innovative medicines in autoimmune and autoinflammatory diseases. We are headquartered in Shanghai, China and have offices in Beijing, China as well in Boston and Chicago, US. Our current pipeline includes 4 small molecules in autoimmune and inflammatory diseases where significant gaps exist. The leading asset, a potent selective JAK1 inhibitor, recently completed global Phase II trials in China, US and Europe in atopic dermatitis, ulcerative colitis and Crohn’s disease.

Currently we are looking for either partnership to develop the AD and/or UC or CD indications for Phase III or out-license the global right excluding China market.

上海元亨祥股权投资基金集团有限公司（简称“元亨祥基金”），2012年8月落户于上海陆家嘴国际金融中心，2014年4月在中国证券投资基金业协会登记为“私募基金管理人”，下设元杏资产（其他类私募基金）、祥乾投资（股权类私募基金）、王道资产（证券类私募基金）。

作为风控型资产管理专家，元亨祥基金始终秉承“专业创造价值，安全方得安心”的品牌理念，顺应国家发展战略，携手世界500强名企太平洋建设、中国建筑、中冶天工等交易对手，积极引导社会资本投资“大基建、大康养、大文旅”领域，累计投资项目超过300个、累计投资规模超过300亿、累计撬动项目总规模超过3000亿，投资足迹遍布全国；同时，凭借投向明确、风控周密、期限合理、业绩领先、产品丰富五大优势，持续专注做好基建投资基金、证券投资基金、特色小镇基金、不动产基金、产业投资基金五大系列基金，为客户倾力打造专属投融资服务。